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Background. Globally, case detection and treatment access are poor for rifampicin-resistant tuberculosis (RR-TB).
The Xpert MTB/RIF test has the potential to increase detection and reduce time to treatment (TTT). However, these
beneﬁts are dependent on health system capacity to provide treatment.
Methods. We retrospectively assessed the impact of Xpert on treatment initiation and TTT in the context of de-
centralized RR-TB care in Khayelitsha, Cape Town, using routine programmatic data. Community-based treatment was
introduced progressively from 2008. Before 2007, diagnosis relied on phenotypic resistance (culture). During 2007–
2008, the line probe assay (LPA) was introduced, followed by Xpert in 2012.
Results. Before decentralization (2003–2006), median TTT was 71 days (interquartile range [IQR], 49–134;
n = 158). The LPA introduction during 2007–2008 was associated with reduced median TTT from 76 to 50 days
(P < .0001, n = 257). Between January 2009 and June 2013, 938 RR-TB cases were diagnosed (74% human immuno-
deﬁciency virus [HIV]-infected). Decentralization during 2008–2011 was associated with declining TTT (P < .0001,
test for trend), a decline to 28 days in 2011 (IQR, 16–40; n = 173). Xpert was associated with a further reduction to
8 days in 2013 (IQR, 5–25; n = 89; P < .0001). Treatment initiation remained unchanged with Xpert and was lower
among HIV-infected (2010–2013); 87.9% (445 of 506) compared with 96.9% (188 of 194) for HIV-uninfected
(P < .0001) patients.
Conclusions. Improved case detection and rapid treatment initiation are required to interrupt transmission and
reduce mortality. In this setting, decentralization was associated with high treatment initiation and reduced TTT.
Xpert implementation signiﬁcantly enhanced the reduction in TTT and has the potential to reduce transmission.
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Direct transmission of drug-resistant tuberculosis (TB)
is driving the epidemic in many high-burden settings
[1, 2]. Therefore, high case detection, rapid diagnosis,
and early treatment initiation are fundamental to re-
ducing ongoing transmission [3]. As yet, however,
case notiﬁcation and access to treatment with second-
line TB drugs remain poor. In 2013, only 20% of esti-
mated multidrug-resistant TB (MDR-TB) cases were
initiated on appropriate treatment globally [4], often
with prolonged delays between a diagnostic sample
and initiation of treatment, resulting in high mortality
and ongoing transmission [5, 6].
Reliance on drug susceptibility testing (DST) using
sputum culture in centralized reference laboratories
limits access and results in delayed treatment. In
2013, less than 10% of bacteriologically conﬁrmed TB
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cases were tested for MDR-TB globally [4]. The Xpert MTB/RIF
test (Cepheid, Sunnyvale, CA) has the potential to both increase
MDR-TB case detection and reduce time to treatment (TTT)
initiation, through diagnosis of rifampicin resistance simul-
taneously with TB diagnosis [7]. Several countries, including
South Africa, have now committed to expanding access to DST
through Xpert, and the World Health Organization now sup-
ports the concept of universal access to DST [8].
However, improving diagnosis is insufﬁcient in itself; health
systems require capacity to treat the increasing numbers of pa-
tients diagnosed with rifampicin-resistant TB (RR-TB). With
the implementation of Xpert in late 2011, South Africa has im-
proved RR-TB case detection dramatically and diagnosed 26 023
cases in 2013, compared with 10 085 in 2011. The proportion of
cases initiating treatment remains low; however, only 41% of di-
agnosed cases in 2013 are reported to have initiated second-line
treatment [4].Although routine recording of the number of cases
starting treatment may be incomplete, the low rate of treatment
uptake is supported by a small study in one province, where only
63% of diagnosed cases initiated treatment [6].
Reliance on centralized treatment in specialist hospitals is likely
to contribute to long delays and lower numbers initiated on treat-
ment, despite the introduction of more rapid diagnostics [9–12].
The introduction of genotypic DST for isoniazid and rifampicin
using the rapid line probe assay ([LPA] Genotype MTBDRplus,
Hain Lifesciences, Nehren, Germany) in place of conventional
culture-based DST signiﬁcantly decreased TTT in 2 rural areas
of South Africa both served by centralized referral hospitals [13,
14]. However, the median TTT in both studies remained at 55 and
62 days with LPA, with signiﬁcant delays reported between LPA
results and treatment initiation. These data suggest that the great-
est beneﬁts will be seen when new diagnostics are introduced in
the context of greater access to treatment through decentralized
and community-based care. We aimed to assess the impact of
Xpert implementation on the proportion of diagnosed cases ini-
tiating treatment and TTT initiation in the context of routine im-
plementation of decentralized RR-TB care and management in
Khayelitsha, a large periurban township in Cape Town.
METHODS
Setting
Khayelitsha township, with a population of approximately
400 000 [15], has one of the highest burdens of human im-
munodeﬁciency virus (HIV) and TB in the country and global-
ly. In 2010, antenatal HIV prevalence was 33% and the TB case
notiﬁcation rate was at least 1500 per 100 000 per year [16, 17].
Rifampicin-resistant TB was found among 4.5% and 11.2% of
new and previously treated TB cases, respectively [2].
A program, developed by Médecins sans Frontières in part-
nership with the City of Cape Town and the Western Cape Pro-
vincial Government, to decentralize RR-TB care and integrate
management into existing primary care TB and HIV services
was implemented in late 2007. Implementation was incremen-
tal, starting with extensive training of primary care clinic staff,
TB infection control interventions, and introduction of clinic-
based RR-TB registers. Additional inputs included the follow-
ing: individual speciﬁc RR-TB counseling, social assistance
and patient support groups, routine home visits and family ed-
ucation, contact tracing and screening, local audiometry screen-
ing, mentoring support for clinicians, initial strengthening of
the standard RR-TB drug regimen, and a local subacute in-pa-
tient service. Patients were hospitalized only if they were clini-
cally unstable and unable to attend their clinic daily for
treatment (a requirement for ambulatory treatment). Treat-
ment was provided through all 11 primary care facilities in the
Khayelitsha subdistrict. This included 8 primary care clinics
and 3 larger community health centres.
The full decentralized model of care has been described pre-
viously [18] along with patient and treatment outcomes [19]. It
is estimated that the complete model of care was in place by
the end of 2010, and the decentralized model has subsequently
been implemented routinely across the City of Cape Town.
Evaluation of the Khayelitsha RR-TB program was approved
the University of Cape Town ethical review committee (Refer-
ence HREC 540/2010).
Drug Susceptibility Testing
During 2007 and 2008, routine DST for rifampicin moved from
conventional culture-based DST (liquid culture for isolation of
M tuberculosis followed by susceptibility testing on solid media)
to LPA, predominantly after a positive liquid culture (culture
with LPA). Direct LPA testing of smear-positive patient samples
(prior to culture) was performed uncommonly and only on spe-
ciﬁc clinician request, but this practice increased over subse-
quent years. Data on whether LPA was conducted from a
cultured or direct specimen was not readily available. Line
probe assay testing initially occurred in a study assessing the
performance of the LPA in the central routine diagnostic labo-
ratory in Cape Town [20]. Hence, over these 2 years, Khayelit-
sha patients were tested with either technique in a random
manner. From January 2009, LPA became the standard for rou-
tine DST for isoniazid and rifampicin (also done in the central
Cape Town laboratory).
Before October 2011, DST was available only for TB cases
considered at high RR-TB risk: those not responding to ﬁrst-
line TB treatment, those previously treated for TB, those with
close RR-TB contacts, healthcare workers, and those with min-
ing or prison history. In late 2011, all individuals with presump-
tive TB were tested with the Xpert MTB/RIF test, which was
conducted in a laboratory located at the district hospital in
Khayelitsha. Although Xpert became the principal TB test, cul-
ture and LPA could also be requested routinely by clinic staff if
considered appropriate (often for Xpert-negative patients).
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Therefore, not all RR-TB patients were diagnosed with Xpert.
All RR-TB cases diagnosed with Xpert were conﬁrmed using
LPA on a second sputum sample submitted at the same time
as the one undergoing Xpert.
Data Collection and Analysis
The study included all patients diagnosed with RR-TB who were
considered to be a resident in Khayelitsha subdistrict. Data from
RR-TB patients diagnosed and treated before January 2008 were
collated retrospectively through a medical record review. Due to
incomplete data on all diagnosed cases in this time period, par-
ticularly those not starting treatment, the percentage of diag-
nosed cases started on treatment was not assessed. From
January 2008, all data on diagnosed RR-TB cases residing in
Khayelitsha were collected prospectively, through paper-based
registers at clinic level (all 11 primary care facilities), with
monthly data entry into an electronic database. Additional
cases diagnosed outside of Khayelitsha (ie, at secondary and ter-
tiary hospitals) were entered based on laboratory reports.
Data from January 2009 until the end of June 2013 were con-
sidered complete and were used to assess the proportion of di-
agnosed cases starting treatment. A minimum of 12 months
follow-up time was allowed to assess treatment initiation.
Time to treatment initiation was determined as the time from
collection of a sputum sample from which rifampicin resistance
was determined to the date second-line anti-TB treatment was
initiated (as recorded in both the register and the patient re-
cord). Patients with microbiologically unconﬁrmed RR-TB
were excluded (predominantly close pediatric contacts of
known cases), as were patients initiating a second treatment ep-
isode for RR-TB. Patients with discordant rifampicin resistance
results by Xpert and LPA were also excluded (14 cases during
2012–2013). Data on percentage of diagnosed cases receiving
treatment (at any point with a minimum of 12 months fol-
low-up time) and TTT were assessed by year(s) to correlate
with stage of decentralized program implementation and DST
method.
Proportions were compared with χ2 analysis (P values mid-P
exact, 2-tailed). Medians were compared with the Mann–
Whitney U test, and changes in TTT over multiple time periods
were assessed with the Jonckheere test. Kaplan-Meier analysis
was used to show TTT, comparing the pre-Xpert time period
(2010–2011) with the Xpert implementation period (2012–
2013). The association of factors with TTT for patients diag-
nosed in 2012–2013 (Xpert as principal diagnostic test) was
performed with multivariate Cox regression, with censoring at
death for patients not started on treatment. Factors considered
to be clinically and programmatically relevant to TTT were as-
sessed in the multivariate analysis, regardless of signiﬁcance on
univariate analysis. These included the following: smear micros-
copy status, whether RR-TB was diagnosed with Xpert, HIV sta-
tus, TB disease site (pulmonary versus extrapulmonary), age,
and sex. All analyses were conducted with IBM SPSS Statistics
(version 22).
RESULTS
Based on the retrospective review, 158 eligible patients were
started on RR-TB treatment before the decentralized program
(2003–2006). During the ﬁrst 2 years of the decentralized pro-
gram (limited decentralization, 2007–2008), 257 cases were re-
corded prospectively as starting treatment (Table 1). Between
January 2009 and June 2013 inclusive, 938 eligible patients
were diagnosed with microbiologically conﬁrmed RR-TB; 74%
were infected with HIV, 49% were female, and the median age
was 33 years (IQR, 26–40). Among these 938 patients, 817
(87%) were initiated on second-line treatment.
Median TTT was similar between patients treated during
2003–2006 and that subset of patients treated during 2007–
2008 who were diagnosed with culture-based DST (P = .45)
(Table 1 and Figure 1). Comparing patients diagnosed with
culture-based DST and those diagnosed using culture with
LPA during the same time period in 2007–2008, the use of
LPA was associated with a signiﬁcantly lower TTT (median
Table 1. Description of Principal Diagnostic Test in use and Model of Care Interventions, Number of RR-TB Patients Diagnosed and










2009 2010 2011 2012 2013a
DST Method
LPA (After Culture or Direct From
Specimen) Xpert
RR-TB model of care Centralized Limited decentralization Improved program
implementation
Full decentralization
No. diagnosed Not available 218 212 195 219 94
No. treated 158 95 162 182 182 173 191 89
% treated Not available 83.5 85.8 88.7 87.2 94.7
Median TTT (days) (IQR) 71 (49–134) 76 (62–111) 50 (38–73) 40 (29–53) 34 (21–51) 28 (16–40) 13 (6–35) 8 (5–25)
Abbreviations: DST, drug susceptibility testing; IQR, interquartile range; LPA, line probe assay; RR-TB, rifampicin-resistant tuberculosis; TTT, time to treatment.
a Half year only (January to June inclusive).
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76 days) compared with culture-based DST (50 days; P < .0001).
The impact of decentralization was assessed by comparing
patients diagnosed by LPA only during 2007–2008 (LPA) and
all patients from the subsequent 3 years; 2009, 2010, and 2011.
During these 4 time periods, there was a signiﬁcant decline in
TTT (P < .0001, test for trend), resulting in a median TTT of 28
days in 2011 (Figure 1). By the end of 2010, implementation of
the decentralized program was complete. Xpert was implement-
ed at the end of 2011 and was associated with a further decline
in TTT to a median of 8 days in 2013 (P < .0001, comparison of
2010–2011 with 2012–2013). Treatment initiation over the
period of Xpert implementation (2012–2013), compared with
the preceding 2-year period (2010–2011), with censoring for
deaths before treatment, is shown in Figure 2.
The percentage of diagnosed patients initiating treatment was
considered accurate from 2009 onwards, and it was consistently
above 80% in this timeframe (Table 1). Although follow-up time
was longer for patients diagnosed in earlier years, only 0.4% (3 of
728) of patients were initiated on treatment beyond 12 months
for the years 2009–2012 inclusive. The introduction of Xpert
(2012–2013) was not associated with an increase in the propor-
tion initiating treatment compared with 2010–2011 (P = .36).
The impact of Xpert implementation on percentage treated and
TTT among patients infected with HIV was also assessed from
2009 onwards (Table 2). Between 2009 and 2013, HIV infection
status was known for 97% (911 of 938) of diagnosed patients.
Among those with unknown HIV status, treatment was initiated
for 22% (6 of 27), with all 6 of these patients refusing HIV
testing. Before Xpert implementation (2009–2011), 93.5% of
HIV-negative patients initiated treatment compared with 85.5%
among patients infected with HIV (P = .001). This difference re-
mained signiﬁcant in 2012–2013 with Xpert implementation;
100% of HIV-negative patients initiated treatment compared
with 88.9% of those with HIV infection (P = .0002). Among
the 24 HIV-infected patients who did not initiate treatment
over this period, 12 (50%) are known to have died before treat-
ment could be initiated. Among those starting treatment, there
was no difference in median TTT by HIV status with either
LPA or Xpert as the principal means of diagnosis (Table 2).
During 2012–2013, with Xpert implementation, only 48%
(150 of 313) of RR-TB cases were actually diagnosed using
Xpert. The remainder were diagnosed predominantly with LPA
after positive culture. Over this same time period (2012–2013,
Xpert implementation), signiﬁcant factors associated with
improved TTT on univariate analysis were sputum smear-positive
Figure 1. Median time to treatment (days) by year and diagnostic method (error bars represent interquartile range). Abbreviations: DST, drug suscept-
ibility testing; LPA, line probe assay.
Figure 2. Time to treatment initiation comparing patients diagnosed in
2010–2011 with those diagnosed in 2012–2013 (Xpert implementation)
(Kaplan–Meier, deaths before treatment censored [○]).
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microscopy status, diagnosis by Xpert, compared with LPA and
pulmonary TB. Both sputum smear positivity and diagnosis by
Xpert (compared with LPA) remained signiﬁcant on multivariate
analysis, with adjusted hazard ratios of 1.65 and 2.29, respectively
(Table 3). Sputum smear positivity remained signiﬁcant in sepa-
rate multivariate analyses among patients diagnosed with Xpert
and those diagnosed with LPA (data not shown).
DISCUSSION
We have previously shown that implementation of a decentral-
ized, community-based program for drug-resistant TB in a high
HIV, TB, and RR-TB setting improved case detection and re-
duced the time between diagnosis and treatment initiation for
RR- TB [19]. The median TTT decreased from more than 70
days before the program to 28 days with the decentralized pro-
gram fully functional and utilizing the LPA as the principal di-
agnostic test. Implementation of the Xpert MTB/Rif test for all
individuals with presumptive TB was associated with a further
reduction in TTT to a median of 7 days in 2013.
However, TTT needs to be viewed in the context of the pro-
portion of diagnosed cases that initiate treatment. Before decen-
tralization, data collection was relatively poor, but, based on
data from elsewhere, it is likely that a signiﬁcant proportion
of diagnosed cases were not started on treatment [6, 21]. Im-
proved staff training, community awareness campaigns, patient
follow-up, and counseling (components of community-based
care) were associated with proportions of diagnosed cases start-
ing treatment consistently above 80%. Given the already high
level of treatment initiation due to decentralization of services,
the slight increase that was seen with Xpert implementation was
Table 2. Number of RR-TB Cases Diagnosed, Treated, and Median TTT by HIV Status and Year(s) in Khayelitsha
2009 2010 2011 2012 2013a
DST Method LPA (After Culture or Direct From Specimen) Xpert
HIV-infected
No. diagnosed 165 154 135 146 71
No. treated 136 131 121 126 67
% treated 82.4 85.1 89.6 86.3 94.4
Median TTT (days) (IQR) 42 (30–57) 34 (22–52) 28 (16–42) 14 (6–35) 8 (5–29)
HIV-negative
No. diagnosed 46 50 57 65 22
No. treated 42 49 52 65 22
% treated 91.3 98.0 91.2 100.0 100.0
Median TTT (days) (IQR) 34 (28–49) 34 (18–49) 25 (16–36) 12 (6–33) 7 (4–14)
Abbreviations: DST, drug susceptibility testing; HIV, human immunodeficiency virus; IQR, interquartile range; LPA, line probe assay; RR-TB, rifampicin-resistant
tuberculosis; TTT, time to treatment.
a Half year only (January to June).
Table 3. Multivariate Cox Regression Analysis of Factors Asso-
ciated With Treatment Initiation Over Time During the Xpert Imple-
mentation Period (n = 313, 2012–2013)a
Factor N (%)
Univariate Multivariate
Hazard Ratio (95% Confidence
Interval)
Smear microscopy status
Smear negative 129 (41%) 1.0 (reference) 1.0 (reference)
Smear positive 144 (46%) 1.60 (1.24–2.08) 1.65 (1.24–2.18)
Missing 40 (13%) 0.64 (0.43–0.95) 0.81 (0.54–1.23)
Xpert diagnosis
No 163 (52%) 1.0 (reference) 1.0 (reference)
Yes 150 (48%) 2.46 (1.92–3.16) 2.29 (1.76–2.97)
HIV status
HIV negative 87 (28%) 1.0 (reference) 1.0 (reference)
HIV infected 217 (69%) 0.80 (0.62–1.03) 1.08 (0.80–1.45)
Missing 9 (3%) 0.00 0.00
TB disease site
Extrapulmonary 24 (8%) 1.0 (reference) 1.0 (reference)
Pulmonary/both 264 (84%) 1.56 (1.01–2.40) 1.03 (0.66–1.63)
Missing 24 (8%) 1.41 (0.60–3.32) 0.75 (0.31–1.81)
Sex
Female 154 (49%) 1.0 (reference) 1.0 (reference)
Male 159 (51%) 1.04 (0.82–1.32) 1.00 (0.78–1.28)
Age
0–19 22 (7%) 1.0 (reference) 1.0 (reference)
20–29 105 (34%) 0.92 (0.56–1.52) 0.84 (0.49–1.44)
30–39 105 (34%) 0.84 (0.51–1.38) 0.86 (0.49–1.49)
40+ 81 (26%) 0.90 (0.54–1.50) 0.91 (0.52–1.59)
Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis.
a Note that an increased hazard ratio represents improved treatment initiation
over time.
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not statistically signiﬁcant; however, this may be different in
other settings with centralized RR-TB services.
Not unexpectedly, treatment initiation over time was signiﬁ-
cantly enhanced when patients were diagnosed using the rapid
Xpert test during 2012–2013, compared with other diagnostic
methods. Approximately half of all cases over this period
were not diagnosed with Xpert, even though Xpert was the prin-
cipal diagnostic test. The most common reason for this was
Xpert-negative results and subsequent culture positivity. This
ﬁnding suggests that, particularly in high HIV-prevalence set-
tings such as this, a single Xpert test may not be sufﬁcient for
improved case detection and that more sensitive methods such
as culture followed by LPA may still be required.
During the same Xpert implementation period (2012–2013),
treatment initiation over time was also signiﬁcantly enhanced for
sputum smear-positive patients, compared with smear-negative
patients. Both of these factors remained signiﬁcant in multivari-
ate analyses, suggesting independent effects. Sputum smear pos-
itivity is an indicator of infectiousness, and, from a public health
perspective, starting these patients on treatment more rapidly
represents signiﬁcant potential to reduce community transmis-
sion, particularly given the rapid reduction in infectiousness
with appropriate treatment recently demonstrated [3].
Given the high early mortality rate among RR-TB patients co-
infected with HIV [5],Xpert may be particularly beneﬁcial in this
group. Although there were similar decreases in TTT between
HIV-infected and uninfected patients with implementation of
the decentralized program, and with Xpert, there was a consistent
difference in the proportion of diagnosed patients initiating treat-
ment with HIV status. Between 2012 and 2013, when Xpert was
in place, 100% of HIV-negative patients initiated treatment com-
pared with 89% of those with HIV. Among the HIV-infected pa-
tients not started on treatment, half are known to have died
before treatment could be initiated, and these deaths occurred
very rapidly. Given that these patients were not initiated on treat-
ment, data on their immune and antiretroviral treatment (ART)
status is largely unknown. However, it is likely that they were not
receiving ART and consequently had low CD4 levels at the time
of diagnosis, contributing to early mortality [22]. Although these
data suggest that earlier diagnosis with a more sensitive, point
of care test might be beneﬁcial, earlier presentation for both
ART and TB diagnosis is required to avert additional mortality
among patients infected with HIV.
The reduction in TTT with the LPA in 2007 and 2008 con-
ﬁrms a previous study showing a similar, signiﬁcant reduction
with use of the LPA [13]. In that study, although TTT was re-
duced, signiﬁcant delays were still observed, conﬁrming the ob-
servation by Jacobson et al [13] that improvements in patient
recall and health system infrastructure were required in order
to see the greatest impacts from new diagnostics. In the absence
of improved capacity to provide treatment, it is likely that the
full beneﬁts of new diagnostics will not be realized.
Although we have shown a signiﬁcant reduction in TTT, the
full impact of Xpert on TTT was probably not seen in the ﬁrst
year (2012) of implementation in Khayelitsha. Implementation
of new diagnostics and new algorithms often take some time to
become embedded into routine practice. In addition, there were
initial concerns about lower positive predictive value in settings
with relatively low proportions of rifampicin resistance [7]. Al-
though it has recently been shown that positive-predictive value
is high for Xpert in Cape Town [23], at the time of this study,
there was no guidance or algorithm in place on how to manage
these patients. Therefore, we excluded the relatively small num-
ber of patients where discordant results between Xpert and the
LPA for rifampicin resistance were observed. Patients with dis-
cordant results are often referred for specialist consideration,
which may result in delayed treatment initiation.
We assessed the impact of various interventions over several
years. Because these interventions were not implemented into a
static healthcare system, it is difﬁcult to attribute direct cause
and effect, particularly with multiple simultaneous interven-
tions. In particular, it would be interesting to assess whether de-
centralization resulted in continued declines in TTT in the
absence of Xpert. Without accurate data on the date that clinics
actually received RR-TB results, it is hard to assess how much
delay is associated with recalling the patient, counseling, and the
treatment initiation process. However, given the median TTT of
28 days in 2011, it is likely that this process was reasonably
streamlined at this point, with limited capacity for further
reductions. Despite this limitation, these are real programmatic
data conﬁrming the beneﬁts of both decentralization of RR-TB
care and Xpert diagnosis for all individuals with presumptive
TB. These ﬁndings are particularly relevant for South Africa,
where access to Xpert has been scaled up but full access to de-
centralized, community-based care is not yet a reality.
The use of routine, programmatic data in this study may also
be considered a limitation. Although data collected retrospective-
ly, before 2009, are likely to be poor, data from 2009 onward were
collected prospectively, with triangulation from several different
sources and continuous data checking and feedback to ensure
quality. Nonetheless, there may have been some patients diag-
nosed and never started on treatment who were missed entirely.
We described TTT initiation from the date that a specimen
was given from which RR-TB was detected. Given that before
2011 not all TB cases were offered DST routinely, it is likely
that some patients had signiﬁcant delays from ﬁrst TB diagnosis
to RR-TB diagnosis, and we have not assessed these delays.
However, this omission is likely to enhance any impact of
Xpert, which includes not just rapid testing but also the poten-
tial to offer DST to all TB cases.
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Simultaneous improvements in case detection and access to
treatment are required in order to avert mortality and reduce
ongoing transmission. The World Health Organization estima-
tes that approximately half a million new cases of MDR-TB
arise annually [4]. In 2013, only 28% of these cases were diag-
nosed, and only 71% of these were started on appropriate treat-
ment, most likely with considerable delays. Xpert has the
potential to increase case detection dramatically, principally
through the opportunity to provide universal drug susceptibility
testing in high TB-burden settings. Xpert also affords the op-
portunity to initiate appropriate second-line treatment rapidly,
offering potential to not only improve patient outcomes but also
to reduce community transmission.
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